euro adhoc: Sygnis Pharma AG
SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Receipt of mandatory offer


Ad Hoc

Heidelberg, 14 November 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) has been informed today that dievini Hopp BioTech holding GmbH & Co. KG will make a compulsory bid to acquire all shares of SYGNIS Pharma AG at an appropriate price. The detailed conditions for the offer will be announced at a later date.

With the compulsory bid dievini Hopp BioTech holding GmbH & Co. KG also fulfils the relevant obligations of the other parties to which the voting rights of dievini Hopp BioTech holding GmbH & Co. KG have to be added. Accordingly, these parties will not make a separate offer.

This announcement has to be regarded in the light of SYGNIS Pharma's recent capital increase at the beginning of November in the course of which dievini Hopp BioTech holding GmbH & Co. KG now owns voting rights of approx. 36%.

@@start.t2@@end of announcement                                                 euro adhoc

ots Originaltext: SYGNIS Pharma AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Franz-Werner Haas
Vice President Operations
Telefon: +49(0)6221 454-812

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX
Börsen:  Börse Frankfurt / regulated dealing/prime standard
              Börse Berlin / free trade
              Börse Hamburg / free trade
              Börse Stuttgart / free trade
              Börse Düsseldorf / free trade
              Börse Hannover / free trade
              Börse München / free trade

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: